Lorlatinib/lorlatinib (lorlatinib) mean resistance time

Lorlatinib/Lorlatinib is a new, reversible, ATPcompetitive small moleculeALK and c-rosoncogene1 (ROS1)Inhibitor. It inhibits tumor cell growth in tumor cells that overexpress ALK and ROS1. Clinical trials have shown that loratinib has a significant therapeutic effect on patients with ALK-positive non-small cell lung cancer. Lorlatinib can also pass the blood-brain barrier and has a good effect on patients with brain metastases.

All drugs develop resistance after a certain period of time, and the same is true for lorlatinib. Judging from relevant data, the average resistance time to lorlatinib is 14 months, but it varies from person to person. Larlatinibcan pass through the blood-brain barrier and has good efficacy in patients with brain metastases. The average resistance time in patients with brain metastases is longer.

Lorlatinib/The recommended dose of lorlatinib is 100 mg taken orally once daily with or without food until disease progression or unacceptable toxicity develops. While taking lorlatinib, swallow the tablet whole. Do not chew, crush, or split the tablet. Do not take if the tablet is broken, cracked, or incomplete. Take lorlatinib at the same time each day. If a dose is missed, take the missed dose unless the next dose is due within 4 hours. Do not take two doses at the same time to make up for a missed dose. If vomiting occurs after taking lorlatinib, do not take additional doses but continue with the next scheduled dose. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.